[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2020115095A3 - Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury - Google Patents

Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury Download PDF

Info

Publication number
WO2020115095A3
WO2020115095A3 PCT/EP2019/083597 EP2019083597W WO2020115095A3 WO 2020115095 A3 WO2020115095 A3 WO 2020115095A3 EP 2019083597 W EP2019083597 W EP 2019083597W WO 2020115095 A3 WO2020115095 A3 WO 2020115095A3
Authority
WO
WIPO (PCT)
Prior art keywords
ischemia
treatment
prevention
compositions
methods
Prior art date
Application number
PCT/EP2019/083597
Other languages
French (fr)
Other versions
WO2020115095A2 (en
Inventor
Lina Badimon Maestro
Judit CUBEDO RÀFOLS
Gemma VILAHUR GARCÍA
Original Assignee
Glycardial Diagnostics, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycardial Diagnostics, S.L. filed Critical Glycardial Diagnostics, S.L.
Priority to CN201980091267.7A priority Critical patent/CN113395994A/en
Priority to JP2021531704A priority patent/JP2022510403A/en
Priority to EP19816630.8A priority patent/EP3890830A2/en
Publication of WO2020115095A2 publication Critical patent/WO2020115095A2/en
Publication of WO2020115095A3 publication Critical patent/WO2020115095A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of Apo J-Glyc in the preventionof ischemia injury, and of both Apo J-Glyc andnon-Glyc Apo J in the treatment of ischemia injury and in the treatment of ischemia-reperfusion injury.
PCT/EP2019/083597 2018-12-05 2019-12-04 Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury WO2020115095A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201980091267.7A CN113395994A (en) 2018-12-05 2019-12-04 Methods and compositions for preventing and/or treating ischemia and treating ischemia/reperfusion injury
JP2021531704A JP2022510403A (en) 2018-12-05 2019-12-04 Methods and compositions for the prevention and / or treatment of ischemic injury and ischemic reperfusion injury
EP19816630.8A EP3890830A2 (en) 2018-12-05 2019-12-04 Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382897.9 2018-12-05
EP18382897 2018-12-05

Publications (2)

Publication Number Publication Date
WO2020115095A2 WO2020115095A2 (en) 2020-06-11
WO2020115095A3 true WO2020115095A3 (en) 2020-07-23

Family

ID=64746472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/083597 WO2020115095A2 (en) 2018-12-05 2019-12-04 Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury

Country Status (4)

Country Link
EP (1) EP3890830A2 (en)
JP (1) JP2022510403A (en)
CN (1) CN113395994A (en)
WO (1) WO2020115095A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075837A2 (en) * 2003-02-21 2004-09-10 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2016090002A1 (en) * 2014-12-04 2016-06-09 Board Of Regents Of The University Of Texas System Recombinant clusterin and use thereof in the treatment and prevention of disease
EP3232200A1 (en) * 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Methods and kits for the diagnosis and risk stratification of patients with ischemia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075837A2 (en) * 2003-02-21 2004-09-10 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2016090002A1 (en) * 2014-12-04 2016-06-09 Board Of Regents Of The University Of Texas System Recombinant clusterin and use thereof in the treatment and prevention of disease
EP3232200A1 (en) * 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Methods and kits for the diagnosis and risk stratification of patients with ischemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOGLIO ELEONORA ET AL: "Exosomal clusterin, identified in the pericardial fluid, improves myocardial performance following MI through epicardial activation, enhanced arteriogenesis and reduced apoptosis", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 197, 14 June 2015 (2015-06-14), pages 333 - 347, XP029251832, ISSN: 0167-5273, DOI: 10.1016/J.IJCARD.2015.06.008 *
GUODONG LIU ET AL: "Clusterin Reduces Cold Ischemia-Reperfusion Injury in Heart Transplantation Through Regulation of NF-kB Signaling and Bax/Bcl-xL Expression", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY., vol. 45, no. 3, 1 January 2018 (2018-01-01), CH, pages 1003 - 1012, XP055585923, ISSN: 1015-8987, DOI: 10.1159/000487295 *
JUDIT CUBEDO ET AL: "Proteomic Signature of Apolipoprotein J in the Early Phase of New-Onset Myocardial Infarction", JOURNAL OF PROTEOME RESEARCH, vol. 10, no. 1, 7 January 2011 (2011-01-07), pages 211 - 220, XP055224821, ISSN: 1535-3893, DOI: 10.1021/pr100805h *
VAN DIJK ANNEMIEKE ET AL: "Intravenous clusterin administration reduces myocardial infarct size in rats", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 40, no. 10, 1 October 2010 (2010-10-01), pages 893 - 902, XP002791076, ISSN: 0014-2972, DOI: 10.1111/J.1365-2362.2010.02345.X *

Also Published As

Publication number Publication date
EP3890830A2 (en) 2021-10-13
CN113395994A (en) 2021-09-14
JP2022510403A (en) 2022-01-26
WO2020115095A2 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
MX2021000710A (en) Compositions comprising bacterial strains.
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
MX2015011898A (en) Pyrazolo compounds and uses thereof.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
GB2541571A (en) Pharmaceutical compositions
NZ708727A (en) Conjugate compounds
MX2020014031A (en) Heterodimeric proteins and uses thereof.
MX2015015518A (en) Methods and compositions for the treatment of cancer.
EP4378535A3 (en) Antibiotic formulations for lower back pain
MX2019004859A (en) Combination treatments comprising administration of imidazopyrazinones.
WO2016040952A3 (en) BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
GB2568181A (en) Wheat
MA48939B1 (en) Compositions comprising bacterial strains
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020001632A (en) Compositions comprising bacterial strains.
WO2016130581A3 (en) Combination cancer therapy
AU2015267160A8 (en) Methods and compositions for preventing ischemia reperfusion injury in organs
MX2021008225A (en) Compositions and methods for treatment of abnormal cell growth.
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
AU2020378127A8 (en) Compounds as CD73 inhibitors
PH12019502915A1 (en) Immunogenic compositions
MX2020012805A (en) Compounds for pain treatment, compositions comprising same, and methods of using same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19816630

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021531704

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019816630

Country of ref document: EP

Effective date: 20210705